We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dummy Cell Receptor Reduces Tumor Size and Spread

By Biotechdaily staff writers
Posted on 20 May 2002
An animal study had found that a specially designed cell receptor may reduce cancer death rates by soaking up excess tumor-produced chemicals like a sponge. The study, led by researchers at the University of California, Irvine (UCI, USA), was reported in the January 2002 issue of Molecular Cancer Therapeutics.

Using human pancreatic cancer cells in mice, the researchers found that the binding of growth factors to dummy receptors--those incapable of sending signals to cells-- had the effect of sharply reducing tumor size and decreasing the spread of cancer cells to other parts of the body. The dummy receptors acted like a sponge, mopping up excess levels of the growth factor TGF-beta, found in cancer cells. Mice with the dummy receptor for TGF-beta showed a 72% reduction in tumor growth one week after injection compared to mice without the receptor. After 50 days, mice with the receptor had an average tumor cell volume of less than 50 cubic mm, while mice without the dummy receptor had tumor cell volume of about 300 cubic mm.

Also, when parts of the tumor cells were injected into mice known to show metastatic spreading, those mice with the dummy receptor showed far less evidence of metastasis than mice without the receptor. In a similar method, dummy receptors for tumor necrosis factor (TNF) are being used clinically to reduce excessive inflammation in arthritis patients.

"This study confirms our earlier findings suggesting that increased levels of TGF-beta make pancreatic cancer cells grow more aggressively,” said Dr. Murray Core, professor of medicine and chief of endocrinology at UCI Medical Center. "We were originally surprised to see these high levels of TGF-beta expressed in pancreatic cancer, since it generally inhibits cell growth. This new role for TGF-beta may lead us to design targeted therapies against pancreatic and other cancers marked by high levels of this growth factor.”

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Clinical Informatics Platform
CLARION™
New
Pipette Calibration System
Artel PCS®

Latest BioResearch News

Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
20 May 2002  |   BioResearch

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
20 May 2002  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
20 May 2002  |   BioResearch